Eslicarbazepine Acetate Tablet
Product Images NDC 43598-685

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Eslicarbazepine Acetate (NDC 43598-685). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr.reddys Laboratories Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Container1 (Container1)

Eslicarbazepine Acetate Tablets 200 mg oral tablets packaging label from Dr. Reddy's Laboratories Inc. The label indicates a 30-tablet bottle, once daily dosing, and includes storage instructions and a QR code linking to the medication guide.*

FDA Label Image

Container2 (Container2)

Label for Eslicarbazepine Acetate Tablets 400 mg, oral tablets, by Dr. Reddy's Laboratories Inc. The label indicates a 30-tablet count for human prescription use with instructions for pharmacists to dispense with the Medication Guide. Includes NDC 43598-685-30 and storage and usage information.*

FDA Label Image

Container3 (Container3)

Label for Eslicarbazepine Acetate Tablets 600 mg by Dr. Reddy's Laboratories Inc. The label states 'Once Daily', includes a NDC number with part of it highlighted, and specifies a tablet count of 60. Storage instructions and a QR code for the medication guide are present, along with a barcode and GTIN. The label indicates the product is for prescription use only.*

FDA Label Image

Container4 (Container4)

Eslicarbazepine Acetate Tablets 800 mg oral tablets packaging label. The label states "Rx Only" and "Once Daily" dosing. It includes a count of 30 tablets and directs pharmacists to dispense with the Medication Guide. The label is marked with the NDC 43598-687 and is from Dr.Reddys Laboratories Inc. Storage and usage instructions are partially visible, along with a QR code and barcode.*

FDA Label Image

Figure1 (Figure1)

A chart depicting fold change and 90% confidence intervals for eslicarbazepine relative to reference, based on factors like age, gender, hepatic impairment, and renal impairment. The chart includes recommendations regarding dose adjustments for each category.*

FDA Label Image

Figure2 (Figure2)

A horizontal forest plot chart showing fold changes and 90% confidence intervals for eslicarbazepine acetate interactions with various drugs, including carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, topiramate, and valproate. The chart includes dose adjustment recommendations where relevant.*

FDA Label Image

Figure3a (Figure3a)

A fold change chart with 90% confidence intervals showing the change in plasma levels of various antiepileptic drugs relative to reference when co-administered with Eslicarbazepine Acetate. Drugs listed include Carbamazepine, Gabapentin, Lamotrigine, Levetiracetam, Phenobarbital, Phenytoin, Topiramate, and Valproate, along with dosing adjustment recommendations where applicable.*

FDA Label Image

Figure3b (Figure3b)

A chart displaying fold change and 90% confidence intervals for various non-AED drugs, statins, oral contraceptives, and warfarin relative to a reference. The graph includes recommendations such as dose adjustments for simvastatin and rosuvastatin, use of alternative birth control with oral contraceptives, and monitoring INR levels for warfarin patients.*

FDA Label Image

Figure4 (Figure4)

A Kaplan-Meier plot showing the estimate of exit rate (%) with 95% confidence intervals for Eslicarbazepine Acetate tablets at 1200 mg and 1600 mg doses. The chart compares results from two studies and historical controls, with sample sizes indicated for each data point.*

FDA Label Image

Figure5 (Figure5)

A bar chart depicting the proportion of patients by percentage reduction in seizure frequency from baseline. It compares data among three groups: Placebo, Eslicarbazepine Acetate 800 mg, and Eslicarbazepine Acetate 1,200 mg, across categories of worse, 0 to <25%, 25 to <50%, 50 to <75%, and 75 to 100% seizure reduction.*

FDA Label Image

Structure (Structure)

Chemical structure diagram of Eslicarbazepine Acetate showing its molecular framework including rings and functional groups such as acetate and amide components.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.